ERC Starting Grant · 2024
Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools
WHY: The heterogeneity of tumors often makes their diagnosis and treatment a very hard task. A single tumor can have many different diagnostically-relevant molecular markers which can also be used to monitor the efficacy of treatment. Innovative, simple, cost-effective, and quantitative analytical tools for diagnostic and therapeutic applications are urgently needed to ensure rapid and appropriate patient care. WHAT: CO-TRANS-NET project addresses this need by developing synthetic nucleic acid units that can respond to a wide range of tumor biomarkers and can provide innovative tools for biosensing and therapeutics through cell-free in-vitro transcription. HOW: The ground-breaking idea of…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.